EGFR-TKIs的治疗药物监测研究进展

吴婷婷, 杨帆, 常珂, 任春霞, 余自成

中国药学杂志 ›› 2023, Vol. 58 ›› Issue (4) : 326-330.

PDF(930 KB)
PDF(930 KB)
中国药学杂志 ›› 2023, Vol. 58 ›› Issue (4) : 326-330. DOI: 10.11669/cpj.2023.04.006
综述

EGFR-TKIs的治疗药物监测研究进展

  • 吴婷婷, 杨帆, 常珂, 任春霞, 余自成
作者信息 +

Research Progress in Therapeutic Drug Monitoring of EGFR-TKIs

  • WU Ting-ting, YANG Fan, CHANG Ke, REN Chun-xia, YU Zi-cheng
Author information +
文章历史 +

摘要

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKIs)在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中发挥了重要作用,越来越多的研究表明,对该类药物开展治疗药物监测(therapeutic drug monitoring,TDM)进行个体化剂量调整可以优化临床治疗结果。笔者聚焦于此类药物的药物浓度-效应关系、药动学差异及其影响因素等内容,综述近十年来对EGFR-TKIs的TDM的研究现状和相关问题,为EGFR-TKIs用于治疗NSCLC过程中充分利用TDM优化患者用药提供参考。

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),play an important role in the treatment of non-small cell lung cancer (NSCLC), and more and more studies indicate that therapeutic drug monitoring for these drugs can be useful. This paper focuses on the concentration-effect relationship, pharmacokinetic variability and influencing factors of these drugs, and reviews the research status and related issues on TDM of EGFR-TKIs in recent ten years, so as to provide reference for further promoting the application of TDM in the treatment of NSCLC with EGFR-TKIs and optimizing medication use.

关键词

表皮生长因子受体酪氨酸激酶抑制剂 / 非小细胞肺癌 / 治疗药物监测 / 药动学变异 / 浓度效应关系

Key words

epidermal growth factor receptor tyrosine kinase inhibitor / non-small cell lung cancer / therapeutic drug monitoring / pharmacokinetic variability / concentration-effect relationship

引用本文

导出引用
吴婷婷, 杨帆, 常珂, 任春霞, 余自成. EGFR-TKIs的治疗药物监测研究进展[J]. 中国药学杂志, 2023, 58(4): 326-330 https://doi.org/10.11669/cpj.2023.04.006
WU Ting-ting, YANG Fan, CHANG Ke, REN Chun-xia, YU Zi-cheng. Research Progress in Therapeutic Drug Monitoring of EGFR-TKIs[J]. Chinese Pharmaceutical Journal, 2023, 58(4): 326-330 https://doi.org/10.11669/cpj.2023.04.006
中图分类号: R979.1   

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] YE L, CHEN X, ZHOU F. EGFR-mutant NSCLC: emerging novel drugs [J]. Curr Opin Oncol, 2021, 33(1): 87-94.
[3] ZHANG X X, GUO Z Y, JIAO W L, et al. Research progress of therapeutic drug monitoring related to tyrohydrotic kinase inhibitors [J]. J China Pharm (中国药房), 2021, 32(1):121-128.
[4] NAKAMURA Y, SANO K, SODA H, et al. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer [J]. J Thorac Oncol, 2010, 5(9): 1404-1409.
[5] ZHAO Y Y, LI S, ZHANG Y, et al. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib [J]. Med Oncol, 2011, 28(3): 697-702.
[6] NI J, LIU D Y, HU B, et al. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer [J]. Cancer, 2015, 121(Suppl 17): 3146-3156.
[7] LIAO D, YAO D, LIU N, et al. Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation [J]. Cancer Chemother Pharmacol, 2018, 82(3): 551-559.
[8] STEFFENS M, PAUL T, HICHERT V, et al. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash [J]. Eur J Cancer, 2016, 55: 131-139.
[9] NAKAO K, KOBUCHI S, MARUTANI S, et al. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer [J]. Sci Rep, 2019, 9(1):18202.
[10] CORRAL J, MOK T S, NAKAGAWA K, et al. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer [J]. Future Oncol, 2019, 15(24): 2795-2805.
[11] BROWN K, COMISAR C, WITJES H, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer [J]. Br J Clin Pharmacol, 2017, 83(6): 1216-1226.
[12] PETERS S, ZIMMERMANN S, ADJEI A A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions [J]. Cancer Treat Rev, 2014, 40(8): 917-926.
[13] SOLASSOL L, PINGUET F, QUANTIN X. FDA-and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management [J]. Biomolecules, 2019, 9(11):668.
[14] LIU D, ZHANG L, WU Y, et al. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer [J]. Lung Cancer, 2015, 89(3):262-267.
[15] KATSUYA Y, FUJIWARA Y, SUNAMI K, et al. Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer [J]. Cancer Chemother Pharmacol, 2015, 76(1): 125-132.
[16] WIND S, SCHNELL D, EBNER T, et al. Clinical pharmacokinetics and pharmacodynamics of afatinib [J]. Clin Pharmacokinet, 2017, 56(3): 235-250.
[17] HU P, CHEN J, LIU D, et al. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect [J]. Eur J Clin Pharmacol, 2015, 71(7): 843-850.
[18] YANG J Z, SONG Y, XIONG J H, et al. The effect of single-dose ougan juice application on the pharmacokinetics of erlotinib [J]. Biomed Res Int, 2021, 2021: 6679082.
[19] HAMILTON M, WOLF J L, RUSK J, et al. Effects of smoking on the pharmacokinetics of erlotinib [J]. Clin Cancer Res, 2006, 12(7): 2166-2171.
[20] BIGOT F, BOUDOU-ROUQUETTE P, ARRONDEAU J, et al. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old [J]. Invest New Drugs, 2017, 35(2): 242-246.
[21] MIZUGAKI H, OIZUMI S, FUJITA Y, et al. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer [J]. Eur J Cancer, 2022, 160: 227-234.
[22] HORAK J, WHITE J, HARRIS A L, et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib [J]. Cancer Chemother Pharmacol, 2011, 68(6): 1485-1495.
[23] O'BRYANT C L, HALUSKA P, ROSEN L, et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function [J]. Cancer Chemother Pharmacol, 2012, 69(3): 605-612.
[24] SCHNELL D, BUSCHKE S, FUCHS H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment [J]. Cancer Chemother Pharmacol, 2014, 74(2): 267-275.
[25] GIRI N, MASTERS J C, PLOTKA A, et al. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib [J]. Invest New Drugs, 2015, 33(4): 931-941.
[26] GRANDE E, HARVEY R D, YOU B, et al. Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment [J]. J Pharmacol Exp Ther, 2019, 369(2): 291-299.
[27] LIAO D, LIU Z, ZHANG Y, et al. Polymorphisms of drug-metabolizing enzymes and transporters contribute to the individual variations of erlotinib steady state trough concentration, treatment outcomes, and adverse reactions in epidermal growth factor receptor-mutated non-small cell lung cancer patients [J]. Front Pharmacol, 2020, 11: 664.
[28] HAYASHI H, ⅡHARA H, HIROSE C, et al. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer [J]. Lung Cancer, 2019, 134: 1-6.
[29] KOBAYASHI H, SATO K, NⅡOKA T, et al. Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in japanese patients with non-small-cell lung cancer [J]. Clin Lung Cancer, 2015, 16(4): 274-281.
[30] SAKAMOTO S, SATO K, TAKITA Y, et al. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib [J]. Invest New Drugs, 2020, 38(6): 1687-1695.
[31] OCCHIPINTI M, BRAMBILLA M, GALLI G, et al. Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors [J]. J Pers Med, 2021, 11(5):424.
[32] ZHANG T, ZHANG K, MA L, et al. Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction [J]. J Pharm Sci, 2018, 107(4):979-983.
[33] VISHWANATHAN K, DICKINSON P A, SO K, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib [J]. Br J Clin Pharmacol, 2018, 84(6): 1156-1169.
[34] YOKOTA H, SATO K, OKUDA Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer [J]. Clin Lung Cancer, 2017, 18(6): e433-e439.
[35] OHGAMI M, KABURAGI T, KUROSAWA A, et al. Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer [J]. Ther Drug Monit, 2018, 40(6): 699-704.
[36] RUIZ-GARCIA A, TAN W, LI J, et al. Pharmacokinetic models to characterize the absorption phase and the influence of a proton pump inhibitor on the overall exposure of dacomitinib [J]. Pharmaceutics, 2020, 12(4):330.
[37] MUTH M, OJARA F W, KLOFT C, et al. Role of TDM-based dose adjustments for taxane anticancer drugs [J]. Br J Clin Pharmacol, 2021, 87(2): 306-316.
[38] MENZ B D, STOCKER S L, VEROUGSTRAETE N, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology [J]. Br J Clin Pharmacol, 2021, 87(2): 227-236.
[39] LI S, ZHANG Q, ZHANG S, et al. Survey on the development of therapeutic drug monitoring in Chinese hospitals in 2018 [J]. Chin Pharm J(中国药学杂志), 2019, 54(24):2087-2092.
[40] CATALÁN-LATORRE A, SUREDA M, BRUGAROLAS-MASLLORENS A, et al. Therapeutic drug monitoring of erlotinib in non-small cell lung carcinoma: a case study[J]. Ther Drug Monit, 2021, 43(4):447-450.
PDF(930 KB)

Accesses

Citation

Detail

段落导航
相关文章

/